Androgen receptors (ARs) have been investigated in female breast carcinoma (FBC), but only a few studies have been performed in male breast carcinoma (MBC). AR expression was retrospectively analysed on formalin-fixed, paraffin embedded tissues from 47 patients with primary MBC at diagnosis using the monoclonal antibody 2F12. 16 cases (34%) were immunopositive. No association was found between AR and patient age, tumour stage, progesterone receptors (PGR) and p53 protein expression. A trend was found for histological grade: 42.8% grade 1-2 cases, but only 8.3% grade 3 tumours were AR positive (p=0.08). A negative association was found between AR and cell proliferative activity: AR negative cases had higher MIB-1 scores (25.4%) than AR positive cases (21.11%; p=0.04). A strong association was found with oestrogen receptors (ER): 15/16 AR positive cases were also ER positive (p=0.0001). In univariate analysis, AR (as well as ER and PGR) were not correlated with overall survival, contrary to tumour histological grade (p=0.02), size (p=0.01), p53 expression (p=0.0008) and MIB-1 scores (p=0.0003). In multivariate survival analysis, only p53 expression (p=0.002) and histological grade (p=0.02) had independent prognostic significance. In conclusion, the lack of association between AR and most clinico-pathological features and survival, and the absence of prognostic value for ER/PGR status, suggest that MBC and FBC are biologically different. Therefore, an antihormonal therapy for patients with MBC seems to be questionable.

Androgen receptors in male breast carcinoma / PICH A; MARGARIA E; CHIUSA L; CANDELARESI G; DAL CANTON O. - In: ARCHIVES D'ANATOMIE ET DE CYTOLOGIE PATHOLOGIQUES. - ISSN 0395-501X. - 46(1998), pp. 312-312. ((Intervento presentato al convegno XXII International Congress of the International Academy of Pathology tenutosi a Nice, France nel October 18-23, 1998.

Androgen receptors in male breast carcinoma

PICH, Achille;
1998

Abstract

Androgen receptors (ARs) have been investigated in female breast carcinoma (FBC), but only a few studies have been performed in male breast carcinoma (MBC). AR expression was retrospectively analysed on formalin-fixed, paraffin embedded tissues from 47 patients with primary MBC at diagnosis using the monoclonal antibody 2F12. 16 cases (34%) were immunopositive. No association was found between AR and patient age, tumour stage, progesterone receptors (PGR) and p53 protein expression. A trend was found for histological grade: 42.8% grade 1-2 cases, but only 8.3% grade 3 tumours were AR positive (p=0.08). A negative association was found between AR and cell proliferative activity: AR negative cases had higher MIB-1 scores (25.4%) than AR positive cases (21.11%; p=0.04). A strong association was found with oestrogen receptors (ER): 15/16 AR positive cases were also ER positive (p=0.0001). In univariate analysis, AR (as well as ER and PGR) were not correlated with overall survival, contrary to tumour histological grade (p=0.02), size (p=0.01), p53 expression (p=0.0008) and MIB-1 scores (p=0.0003). In multivariate survival analysis, only p53 expression (p=0.002) and histological grade (p=0.02) had independent prognostic significance. In conclusion, the lack of association between AR and most clinico-pathological features and survival, and the absence of prognostic value for ER/PGR status, suggest that MBC and FBC are biologically different. Therefore, an antihormonal therapy for patients with MBC seems to be questionable.
XXII International Congress of the International Academy of Pathology
Nice, France
October 18-23, 1998
46
312
312
Male breast carcinoma; androgen receptor
PICH A; MARGARIA E; CHIUSA L; CANDELARESI G; DAL CANTON O
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/83596
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact